Article

Public Preferences for End-of-Life Timing in Alzheimer Disease and Related Dementias

2026-07-29

Abstract excerpt

Alzheimer’s Disease and Related Dementias (ADRD) impacts 7 million people in the US over the age of 65, costing $360B in reimbursable care and $347B in unpaid care annually. ADRD is a salient health issue, being the most feared medical condition in the US and surpassing a fear of cancer. Despite this concern, there is almost no data about how Americans view their future lives if they receive an ADRD diagnosis. To...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 51b70d29-e7bf-591f-a794-a02e0677eac6
DOI: 10.64898/2026.07.25.26358937

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Public Preferences for End-of-Life Timing in Alzheimer Disease and Related DementiasDOI 10.64898/2026.07.25.26358937Read

Considerations regarding a diagnosis of Alzheimer’s Disease before dementia: a systematic reviewSemantic proximity Read

Predictors of Willingness to Enroll in Hypothetical Alzheimer Disease Biomarker Studies that Disclose Personal ResultsSemantic proximity Read

General healthcare preferences for people aged 50 and over in England: English Longitudinal Study of AgeingSemantic proximity Read

Ethical and social implications of approaching death prediction in humans - when the biology of ageing meets existential issuesSemantic proximity Read

Public perceptions of presymptomatic testing for Alzheimer disease.Semantic proximity Read

PREFER-DMT: A Discrete Choice Experiment Framework for Eliciting Stakeholder Preferences on Disease-Modifying Therapy Implementation in European Healthcare SystemsSemantic proximity Read

"It seems enormously valuable to me." Perspectives of Dutch (potential) carriers of genetic FTD on onset-predictive biomarker testing.Semantic proximity Read

Physician estimates of the feasibility of preserving the dying for future revivalSemantic proximity Read

Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer's disease-type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learningSemantic proximity Read

Consumer preferences for the predictive genetic test for Alzheimer disease.Semantic proximity Read

Experiences of and recommendations on clinical trial design in Alzheimer’s disease from the participant’s point of viewSemantic proximity Read

Implementing advance care planning in dementia care: results and insights from a pilot interventional trialSemantic proximity Read